Indegene growth ratios

Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025
+23.6%+9.6%
+15.9%+5.7%
+8.5%+5.8%
−1.4%+20.8%
−2.5%+12.9%
+38.9%+30.7%
+20.0%+83.0%
+47.3%−13.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDGN₹593.45

Indegene Ltd.

· Pharma & Health
₹ CrorePeersSYNGENELTTSGRANULESJUBLPHARMAKIMSERISEMCUREONESOURCEMcap ₹14,272 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+9.6+23.6—
EBITDA Growth—+5.7+15.9—
EBIT Growth—+5.8+8.5—
Net Income Growth—+20.8-1.4—
EPS Growth—+12.9-2.5—
Total Assets Growth—+30.7+38.9—
Total Equity Growth—+83.0+20.0—
Cash from Operations Growth—-13.0+47.3—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.